Immuno-Oncology | Specialty

Heterogeneity of Metastatic HR+ Breast Cancer

October 2nd 2017

Understanding Abemaciclib: A New CDK4/6 Inhibitor

October 2nd 2017

CDK4/6 Inhibitor Combinations for HR+ mBC

October 2nd 2017

ER+/HER2+ Metastatic Breast Cancer

October 2nd 2017

Future Directions: CDK4/6 Inhibitors in Breast Cancer

October 2nd 2017

Treatment Selection for HR+ mBC

October 2nd 2017

mBC: CDK4/6 Inhibitor Patient Selection/Sequencing

October 2nd 2017

CDK4/6 Inhibitors in Breast Cancer: Ongoing Research

October 2nd 2017

FDA Approval for Abemaciclib

October 2nd 2017

MONARCH 3: Abemaciclib With Endocrine Therapy for mBC

October 2nd 2017

MONARCH 1: Abemaciclib Monotherapy for HR+ mBC

October 2nd 2017

Abemaciclib + Fulvestrant at Progression of HR+ mBC

October 2nd 2017

Abemaciclib for ER+ mBC

October 2nd 2017

CDK4/6 Inhibitors: Managing Toxicity in HR+ mBC

October 2nd 2017

Clinical Experience: CDK4/6 Inhibitors in Breast Cancer

October 2nd 2017

CDK 4/6 Inhibitors in Metastatic Breast Cancer

October 2nd 2017

Future Directions in NSCLC Immuno-Oncology Research

September 28th 2017

Immuno-Oncology Combination Therapy in NSCLC

September 28th 2017

Promising Immunotherapy Agents for NSCLC

September 28th 2017

PACIFIC Trial: Durvalumab for Stage 3 NSCLC

September 28th 2017